Over 1000 Patients Have Benefited from Stentys Self-Apposing Technology
PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS S.A. (FR0010949404, STNT.PA), a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that its Self-Apposing Stent has been implanted into more than 1000 patients internationally.